ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Why Teladoc (TDOC) Shares Are Getting Obliterated Today

TDOC Cover Image

What Happened?

Shares of digital medical services platform Teladoc Health (NYSE: TDOC) fell 6% in the afternoon session after analyst forecasts pointed to a significant slowdown in the company's future growth compared to the broader industry. Analysts watching the company estimated its growth at only 2.2% per year over the next three years. In contrast, the rest of the healthcare technology industry was projected to expand by a much more attractive 12% annually. This large gap in expected performance likely made investors uncomfortable, as it suggested Teladoc could be facing a less prosperous future than its peers.

The shares closed the day at $8.13, down 5.8% from previous close.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Teladoc? Access our full analysis report here.

What Is The Market Telling Us

Teladoc’s shares are extremely volatile and have had 48 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 4 days ago when the stock gained 6.3% on the news that the company reported third-quarter financial results that surpassed Wall Street's revenue expectations, even as other key metrics declined compared to the previous year. Teladoc posted revenue of $626.4 million, which represented a 2.2% year-over-year decline but came in slightly ahead of analyst forecasts. The company's adjusted EBITDA of $66.07 million also topped estimates. However, the company's GAAP loss of $0.28 per share was wider than Wall Street had anticipated. The stock's positive reaction suggests investors focused on the revenue and EBITDA beats, viewing the results as better than feared. Adding to this sentiment, Teladoc's revenue guidance for the next quarter was roughly in line with expectations, reassuring investors about the near-term outlook.

Teladoc is down 15.1% since the beginning of the year, and at $8.08 per share, it is trading 43.6% below its 52-week high of $14.33 from February 2025. Investors who bought $1,000 worth of Teladoc’s shares 5 years ago would now be looking at an investment worth $41.38.

P.S. In tech investing, "Gorillas" are the rare companies that dominate their markets—like Microsoft and Apple did decades ago. Today, the next Gorilla is emerging in AI-powered enterprise software. Access the ticker here in our special report.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.69
+0.14 (0.06%)
AAPL  268.56
+1.12 (0.42%)
AMD  223.55
-6.74 (-2.93%)
BAC  52.02
+0.38 (0.74%)
GOOG  292.99
+8.03 (2.82%)
META  590.32
-7.37 (-1.23%)
MSFT  487.05
-6.74 (-1.36%)
NVDA  186.52
+5.16 (2.85%)
ORCL  225.53
+5.04 (2.29%)
TSLA  403.99
+2.74 (0.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.